Literature DB >> 9915662

Mechanistic studies of high-density lipoproteins.

M L Kashyap1.   

Abstract

There is increasing evidence that high-density lipoprotein (HDL) and its subfractions are protective against atherosclerotic cardiovascular disease. Physical exercise, weight reduction, smoking cessation, diabetes mellitus control, and specific drugs, including niacin, fibrates, and estrogens, are effective methods to increase HDL levels. Niacin is the oldest and most powerful clinical agent for raising HDL levels. Niaspan, an extended-release niacin formulation, is as potent as immediate-release niacin in increasing levels of HDL cholesterol; subfractions HDL2 and HDL3; apolipoprotein A-I, the major protein of HDL, and its cardioprotective subfraction lipoprotein A-I. Recent research from our laboratory suggests a novel mechanism by which niacin inhibits hepatic removal of HDL-apoprotein A-I without interfering with the removal of cholesterol carried by HDL, thus augmenting reverse cholesterol transport. Other mechanistic studies indicate that fibrates and estrogens stimulate the synthesis and production of HDL-apoprotein A-I. Because niacin decreases HDL-apoprotein A-I removal, and fibrates and estrogens increase HDL-apoprotein A-I production, combinations of niacin with these agents may raise HDL levels more than fibrates or estrogens alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9915662     DOI: 10.1016/s0002-9149(98)00813-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 2.  The benefits of niacin in atherosclerosis.

Authors:  S Tavintharan; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

3.  HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.

Authors:  Gerald F Watts; John R Burnett
Journal:  Clin Biochem Rev       Date:  2004-02

4.  Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat.

Authors:  Songul Suren Castillo; M Mutluhan Doger; Sehnaz Bolkent; Refiye Yanardag
Journal:  Mol Cell Biochem       Date:  2007-10-13       Impact factor: 3.396

Review 5.  Mechanism of action of niacin on lipoprotein metabolism.

Authors:  V S Kamanna; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

Review 6.  Niacin dosing: relationship to benefits and adverse effects.

Authors:  D M Capuzzi; J M Morgan; O A Brusco; C M Intenzo
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

7.  Guanabenz-an old drug with a potential to decrease obesity.

Authors:  Magdalena Kotańska; Joanna Knutelska; Noemi Nicosia; Kamil Mika; Małgorzata Szafarz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-05       Impact factor: 3.195

8.  Beneficial Effects of Coenzyme Q10 Supplementation on Lipid Profile and Intereukin-6 and Intercellular Adhesion Molecule-1 Reduction, Preliminary Results of a Double-blind Trial in Acute Myocardial Infarction.

Authors:  Mona Mohseni; Mohammadreza Vafa; Mitra Zarrati; Farzad Shidfar; Seyed Javad Hajimiresmail; Abbas Rahimi Forushani
Journal:  Int J Prev Med       Date:  2015-08-07

9.  Effects of coenzyme q10 supplementation on serum lipoproteins, plasma fibrinogen, and blood pressure in patients with hyperlipidemia and myocardial infarction.

Authors:  Mona Mohseni; Mohamad Reza Vafa; Seyed Javad Hajimiresmail; Mitra Zarrati; Abbas Rahimi Forushani; Vida Bitarafan; Farzad Shidfar
Journal:  Iran Red Crescent Med J       Date:  2014-10-05       Impact factor: 0.611

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.